Research programme: HIV-1 fusion inhibitors - Panacos Pharmaceuticals
Alternative Names: PA 161Latest Information Update: 04 Nov 2017
At a glance
- Originator Panacos Pharmaceuticals Inc
- Class Small molecules
- Mechanism of Action HIV fusion inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported HIV-1 infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in HIV-1-infections in USA (PO)
- 05 Mar 2008 A lead compound has been selected for preclinical development
- 15 Mar 2005 Panacos Pharmaceuticals has been acquired and merged into V.I. Technologies